Floatz logo

Busulphan

Inborn Error Of Immunity

medac GmbHPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Inborn Error Of Immunity cohort.

Asset / SponsorPhaseRating
Treosulfan
medac GmbH
Phase 2B
Fludarabine
Paul Szabolcs
Phase 2B
Hydroxyurea
Paul Szabolcs
Phase 2CCC
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Clofarabine
University of California, San Francisco
Phase 2CCC

View all 15 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →